NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Vemurafenib for the treatment of unresectable locally advanced or metastatic, BRAF^{V600} mutation positive malignant melanoma

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator Email: TACommA@nice.org.uk Fax: +44 (0)20 7061 9721 Post: NICE, MidCity Place, 71 High Holborn, London, WC1V 6NA

I confirm that:		٠, ٠	ROYAL COLLEGE OF
Physician's Lagree nomina statement	hat: with the content of the state ating orgnanisation] and conse	ment submitted equently I will no	l by [insert name of t be submitting a personal
Name:	MARTIN	GORE	
Signed:			
Date:		29/31	n